Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Sikander Ailawadhi, Antje Hoering, J Christine Ye, Brea Lipe, Thomas R. Chauncey, Krisstina Gowin, David Calverley, Sarah A. Holstein, Erica L. Campagnaro, Adam Rosenthal, Jack Aiello, Saad Z. Usmani, Vincent Rajkumar, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3381.3.

https://doi.org/10.1182/blood-2024-209626

Published: 2024

Journal Articles

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian A. Walker, Vaishali Sanchorawala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D'Souza, Heather J. Landau, Adam Rosenthal, Antje Hoering, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3309.1.

https://doi.org/10.1182/blood-2024-208227

Published: 2024

Journal Articles

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

Angela C Weyand, Michelle Sholzberg, Jacob S Lai, Benjamin Kim, Adam Rosenthal, Scott M Robertson, Gary Patou, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2024-206567

Published: 2024

Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-143180

Published: 2020

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients

Valeriy V Lyzogubov, MD PhD, Pingping Qu, Cody Ashby, PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2018-99-117067

Published: 2018

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Cody Ashby, PhD, Eileen Boyle, Ruslana G. Tytarenko, MS, Hongwei Wang, MS, Adam Rosenthal, MS, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 110.

https://doi.org/10.1182/blood-2018-99-113045

Published: 2018

Journal Articles

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Blood (2018) 132 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2018-99-113169

Published: 2018

Journal Articles

Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time

Katherine K Nishimura, Brian A Walker, PhD, Adam Rosenthal, MS, Faith E. Davies, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Antje Hoering, PhD

Blood (2018) 132 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2018-99-118605

Published: 2018

Journal Articles

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood (2018) 132 (6): 587–597.

https://doi.org/10.1182/blood-2018-03-840132

Published: 2018

Includes: Supplemental data

Journal Articles

Incidence of Thromboembolic Events Is Increased in a Retrospective Analysis of a Large Cold Agglutinin Disease (CAD) Cohort

Catherine Broome, MD, Julia M Cunningham, MD, Megan Mullins, MPH, Xiaohui Jiang, MS, Lauren Bylsma, MPH, Jon Fryzek, MPH, PhD, Adam Rosenthal, PhD

Blood (2017) 130 (Supplement 1): 928.

https://doi.org/10.1182/blood.V130.Suppl_1.928.928

Published: 2017

Journal Articles

The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup

Caleb K. Stein, MS, Charlotte Pawlyn, MB BChir, Shweta S. Chavan, PhD, Niels Weinhold, PhD, Brian A Walker, PhD, Adam Rosenthal, Ola Landgren, MD, PhD, Peter Leif Bergsagel, MD PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4441.

https://doi.org/10.1182/blood.V128.22.4441.4441

Published: 2016

Journal Articles

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Sharmilan Thanendrarajan, MD, Daisy V. Alapat, MD, Maurizio Zangari, MD, Carolina Schinke, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Adam Rosenthal, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 1843.

https://doi.org/10.1182/blood.V126.23.1843.1843

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Bounleut Phanavanh, Priyangi Malaviarachchi, Adam Rosenthal, Yogesh Jethava, MB, MRCP, MD FRCPath, Bart Barlogie, MD PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2014) 124 (21): 2012.

https://doi.org/10.1182/blood.V124.21.2012.2012

Published: 2014

Journal Articles

Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment

Caleb K Stein, MS, Pingping Qu, PhD, Joshua Epstein, DSc, Adam Rosenthal, Rachel Hunter-Merrill, Ryan Williams, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3355.

https://doi.org/10.1182/blood.V124.21.3355.3355

Published: 2014

NARROW

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Incidence of Thromboembolic Events Is Increased in a Retrospective Analysis of a Large Cold Agglutinin Disease (CAD) Cohort

The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only